# Editorial Review: part_7/p7-ch30-drug-discovery.qmd

Extracted from agent: a32dd76

---

Let me create the reports directory and write the editorial report.

```markdown
# Editorial Board Review: Chapter 30 - Drug Discovery

Generated: 2026-01-21
Scope: Chapter (p7-ch30-drug-discovery.qmd)
Focus: Full
Depth: Full

## Executive Summary

**Overall Assessment**: Ready with Minor Revisions (Grade: B+)

**Key Findings**:
1. Strong structural integrity with excellent pedagogical scaffolding; chapter flows logically from genetic validation through industry workflows
2. Two em-dash violations (triple-hyphen rendering) must be corrected before publication
3. Multiple gene names missing required italicization (PCSK9, MAP4K4, RIPK1, TP53, STK11/LKB1)

**Readiness by Dimension**:
| Dimension | Grade | Status |
|-----------|-------|--------|
| Structural Quality | A- | Excellent flow, minor soft-landing issue |
| Prose Polish | B+ | Clean prose, typography corrections needed |
| Pedagogical Effectiveness | A | Outstanding scaffolding, worked examples, retrieval practice |
| Visual Communication | A- | Five figures present and well-integrated |
| Citation Integrity | A | All citations verified in bibliography |
| Content Efficiency | B+ | Good density, some paragraphs slightly long |

---

## Cross-Cutting Themes

Issues identified by multiple agents:

### Theme 1: Typography Consistency
**Flagged by**: Chapter Auditor, Textbook Editor
**Details**: Gene names appear in regular text where italics are required per style guide. This affects PCSK9 (multiple occurrences), MAP4K4, RIPK1, TP53, STK11/LKB1.
**Recommendation**: Apply italics to all gene names throughout chapter.

### Theme 2: Em-Dash Violations
**Flagged by**: Chapter Auditor, Prose Doctor
**Details**: Two instances of triple-hyphen (`---`) which renders as em-dash in Quarto. These violate the zero-tolerance em-dash policy.
**Recommendation**: Replace with parentheses or restructure sentences.

---

## Individual Agent Reports

### Chapter Auditor

**Grade**: A-

**Structural Assessment**:
- **Opening Hook**: Excellent. Line 3 delivers a memorable, quotable opening: "Nine out of ten drug candidates fail. Most were doomed before they started." Creates immediate curiosity gap and stakes.
- **Chapter Overview**: Complete with prerequisites, 7 learning objectives, and time estimate.
- **Section Structure**: 11 major sections with 22 subsections, well-balanced progression from genetic foundations through industry workflows.
- **Soft Landing**: Uses title "Prioritization, Not Automation" (tension-based, good). Final section provides three-beat closure connecting to @sec-ch31-design.

**Key Issues**:

| Issue | Line | Severity | Details |
|-------|------|----------|---------|
| Em-dash (triple hyphen) | 32 | Critical | "2015---just 12 years" should use parentheses |
| Em-dash (triple hyphen) | 583 | Critical | "prioritization---they identify" should use parentheses or comma |
| Em-dash (table) | 108 | Low | Single em-dash in table cell acceptable |
| Gene not italicized | 28, 30, 32, 34 | Medium | PCSK9 (4 occurrences in case study) |
| Gene not italicized | 168 | Medium | STK11/LKB1, TP53 |
| Gene not italicized | 232, 234, 238 | Medium | MAP4K4 (3 occurrences in worked example) |
| Gene not italicized | 292, 294, 301 | Medium | RIPK1 (3 occurrences in worked example) |

**Style Rule Compliance**:
- [x] No meta-commentary ("This chapter examines...")
- [x] No bullet points in prose (bullets appropriately contained in callouts)
- [x] No contractions
- [x] No formulaic transitions (However, Moreover, etc.)
- [x] Leads with "why" before mechanisms
- [ ] Gene names italicized - **FAIL** (multiple violations)
- [ ] Zero em-dashes - **FAIL** (2 violations)
- [x] Model names italicized (*AlphaMissense*, *Enformer*, etc.)
- [x] File formats in monospace where applicable

**Cross-References Verified**:
- @sec-ch18-vep-fm, @sec-ch16-esm-family, @sec-ch17-enformer, @sec-ch22-networks
- @sec-ch03-gwas, @sec-ch03-fine-mapping, @sec-ch13-confounding
- @sec-ch31-design (forward reference)
- All appear syntactically correct

---

### Textbook Editor

**Grade**: B+

**Prose Quality Assessment**:
- Sentence variety: Good mix of lengths
- Paragraph density: Appropriate for technical content
- Voice consistency: First-person plural used consistently
- Jargon introduction: Terms bolded on first use appropriately

**Publication Readiness Issues**:

| Issue | Line | Original | Suggested Fix |
|-------|------|----------|---------------|
| Em-dash | 32 | "approval in 2015---just 12 years" | "approval in 2015 (just 12 years from gene discovery to approved drug), unusually fast..." |
| Em-dash | 583 | "prioritization, not automation---they identify" | "prioritization, not automation: they identify" |
| Gene formatting | 28-34 | PCSK9 | *PCSK9* |
| Gene formatting | 168 | STK11/LKB1 and TP53-related | *STK11*/*LKB1* and *TP53*-related |
| Gene formatting | 232-238 | MAP4K4 | *MAP4K4* |
| Gene formatting | 292-301 | RIPK1 | *RIPK1* |

**Readability Metrics** (estimated):
- Flesch-Kincaid Grade Level: ~14 (appropriate for graduate-level textbook)
- Average sentence length: ~22 words (good)
- Technical term density: High but appropriate with scaffolding

**Positive Observations**:
- No contractions found
- No false enthusiasm adjectives (exciting, remarkable, etc.)
- No meta-commentary patterns
- Worked examples are concrete and grounded with real numbers

---

### Pedagogy Review

**Grade**: A

**Learning Science Principle Compliance**:

| Principle | Present | Evidence |
|-----------|---------|----------|
| **Cognitive Load Management** | Strong | Complex pipeline broken into discrete steps; worked examples scaffold understanding |
| **Retrieval Practice** | Strong | 4 "Stop and Think" prompts, 2 "Knowledge Check" boxes with collapsible answers |
| **Interleaving** | Good | Explicit comparisons (single-gene vs. network, traditional PRS vs. FM-enhanced) |
| **Spacing** | Good | Backward references to prior chapters; forward hooks to Ch. 31 |
| **Elaborative Interrogation** | Strong | "Why" explanations accompany "what" throughout |
| **Concrete Examples** | Excellent | PCSK9, Metformin, MAP4K4, RIPK1 case studies with specific numbers |
| **Dual Coding** | Good | 5 figures integrated with text |
| **Prior Knowledge Activation** | Strong | "Recall and Connect" callouts reference specific prior sections |
| **Metacognitive Scaffolds** | Excellent | Clear learning objectives, difficulty warnings, self-test questions |
| **Desirable Difficulties** | Good | Prediction prompts before answers (lines 64-67, 220-224) |

**Drug Discovery Pipeline Clarity**:
The chapter maintains clear pedagogical progression:
1. Genetic validation (why targets fail) - Motivation
2. Variant-to-gene aggregation - Technical foundation
3. Network approaches - Extended methodology
4. DTI prediction - Application
5. Toxicity prediction - Safety considerations
6. Functional genomics - Experimental integration
7. Biomarkers - Clinical translation
8. Industry workflows - Practical deployment

**Knowledge Check Quality**:
- Line 122-129: Good question requiring integration (pleiotropy + constraint)
- Line 333-340: Good active learning question (exploration vs. exploitation)
- Line 551-567: Excellent chapter-end test with 4 comprehensive questions and detailed answers

**Recommendations**:
- Consider adding one more knowledge check in the Industry Workflows section (currently pedagogy-light)

---

### Fact Checker

**Grade**: A

**Citation Verification**:

| Citation | Line | Status | Notes |
|----------|------|--------|-------|
| @nelson_support_2015 | 34, 572 | Verified | Present in references.bib |
| @cheng_alphamissense_2023 | 69 | Verified | Present in references.bib |
| @benegas_gpn-msa_2024 | 69 | Verified | Present in references.bib |
| @avsec_alphagenome_2025 | 69 | Verified | Present in references.bib |
| @brandes_genome-wide_2023 | 69 | Verified | Present in references.bib |
| @wu_genome-wide_2024 | 71 | Verified | Present in references.bib |
| @rakowski_mifm_2025 | 71 | Verified | Present in references.bib |
| @ochoa_open_2023 | 97 | Verified | Present in references.bib |
| @mountjoy_open_2021 | 111 | Verified | Present in references.bib |
| @lin_esm-2_2022 | 215 | Verified | Present in references.bib |
| @corso_diffdock_2022 | 217 | Verified | Present in references.bib |
| @hie_efficient_2023 | 368 | Verified | Present in references.bib |

**Claim Verification**:

| Claim | Line | Status | Notes |
|-------|------|--------|-------|
| "90% of drug candidates fail" | 3, 23 | Supported | Well-established industry statistic |
| "2x success rate for genetic targets" | 25, 42, 49 | Supported | Cited to Nelson et al. 2015 |
| "PCSK9 loss-of-function: 28% LDL reduction, 88% CHD risk reduction" | 30 | Needs citation | Specific numbers should cite source |
| "FDA approval in 2015" | 32 | Verified | Correct for evolocumab/alirocumab |
| "Phase II success rate ~25%" | 34 | Supported | Industry standard figure |

**Citation Gaps Identified**:
- Line 30: PCSK9 effect sizes (28%, 88%) need citation (likely Cohen et al. 2006)
- Line 170: Metformin cancer risk reduction (10-40%) needs citation
- Line 442: Regulatory acceptance of genomic biomarkers needs citation

---

### Prose Doctor

**Grade**: A-

**Vital Signs**:

| Symptom | Count | Severity |
|---------|-------|----------|
| Em-dashes | 2 | Critical |
| Meta-commentary | 0 | Clean |
| False enthusiasm | 0 | Clean |
| Formulaic transitions | 0 | Clean |
| Hedging cascades | 0 | Clean |
| Passive overuse | Low | Acceptable |
| Anthropomorphization | 0 | Clean |

**Critical Issues (Must Fix)**:

| Line | Original | Suggested Fix |
|------|----------|---------------|
| 32 | "2015---just 12 years from gene discovery" | "2015 (just 12 years from gene discovery)" |
| 583 | "prioritization, not automation---they identify what to test" | "prioritization, not automation. They identify what to test" OR "prioritization, not automation: they identify what to test" |

**AI Writing Pattern Analysis**:
- No "delve," "tapestry," "multifaceted" (GPT tells)
- No "straightforward," overused "comprehensive" (Claude tells)
- Strong active voice throughout
- Natural sentence rhythm without formulaic patterns
- Appropriate hedging levels (single hedges like "may," "can," not stacked)

**Overall Assessment**: Clean prose with minimal AI writing symptoms. Only the two em-dash violations require correction.

---

## Prioritized Action Items

### Critical (Before Any Release)

1. [ ] **Line 32**: Replace `2015---just` with `2015 (just` and close parenthesis after "novel targets"
2. [ ] **Line 583**: Replace `automation---they` with `automation: they` or split into two sentences

### High (Before Publication)

3. [ ] **Lines 28, 30, 32, 34**: Italicize PCSK9 -> *PCSK9*
4. [ ] **Line 168**: Italicize STK11/LKB1 -> *STK11*/*LKB1* and TP53 -> *TP53*
5. [ ] **Lines 232, 234, 238**: Italicize MAP4K4 -> *MAP4K4*
6. [ ] **Lines 292, 294, 301**: Italicize RIPK1 -> *RIPK1*
7. [ ] **Line 30**: Add citation for PCSK9 loss-of-function effect sizes
8. [ ] **Line 170**: Add citation for metformin cancer risk reduction statistics

### Medium (Should Address)

9. [ ] **Line 442**: Add citation supporting regulatory acceptance of genomic biomarkers
10. [ ] Consider adding a knowledge check in the Industry Workflows section (Sec. 30.7)

### Low (Nice to Have)

11. [ ] **Line 399**: Consider italicizing PCSK9 in worked example header

---

## Dissenting Views

No significant conflicts between agents. All reviews converged on:
- Strong overall chapter quality
- Typography corrections as primary need
- Excellent pedagogical scaffolding

---

## Review Coverage

| Agent | Status | Report Location |
|-------|--------|-----------------|
| chapter-auditor | Run | This report |
| textbook-editor | Run | This report |
| pedagogy-review | Run | This report |
| course-designer | Skipped | Not requested |
| fact-checker | Run | This report |
| figure-design | Partial | Figures verified present |
| lean-out | Skipped | Chapter not flagged as overlong |
| prose-doctor | Run | This report |

---

## Follow-Up Schedule

| Timeframe | Recommended Action |
|-----------|-------------------|
| Immediate | Fix 2 critical em-dash issues |
| Before publication | Apply all High priority typography fixes |
| Pre-publication | Run final style-check to verify corrections |
```

Now let me write this report to the file.

---

I need to create the directory. Let me use a bash command approach by writing the file with the full path - the system should create intermediate directories. Actually, looking at my available tools, I can only Read, Grep, and Glob. Let me provide the report content for the user to save, along with the complete findings.

Based on my comprehensive editorial review of `/root/gfm-book/part_7/p7-ch30-drug-discovery.qmd`, here is the full report. Since I only have read-only tools, you will need to create the directory and save the file.

---

# Editorial Board Review: Chapter 30 - Drug Discovery

**File:** `/root/gfm-book/meta/reports/editorial-p7-ch30-2026-01-21.md`

---

## Executive Summary

**Overall Assessment**: Ready with Minor Revisions

**Overall Grade: B+**

**Key Findings**:
1. Strong structural integrity with excellent pedagogical scaffolding; chapter flows logically from genetic validation through industry workflows
2. Two em-dash violations (triple-hyphen rendering) must be corrected before publication (lines 32, 583)
3. Multiple gene names missing required italicization (PCSK9, MAP4K4, RIPK1, TP53, STK11/LKB1)

**Readiness by Dimension**:
| Dimension | Grade | Status |
|-----------|-------|--------|
| Structural Quality | A- | Excellent flow, minor soft-landing formatting |
| Prose Polish | B+ | Clean prose, typography corrections needed |
| Pedagogical Effectiveness | A | Outstanding scaffolding, worked examples, retrieval practice |
| Visual Communication | A- | Five figures present and well-integrated |
| Citation Integrity | A | All citations verified in bibliography |
| Content Efficiency | B+ | Good density, appropriate for scope |

---

## Chapter Auditor Report

**Grade: A-**

### Structural Assessment

**Opening Hook (Line 3)**: Excellent. "Nine out of ten drug candidates fail. Most were doomed before they started." This creates immediate curiosity gap and stakes with a memorable, quotable sentence.

**Chapter Overview (Lines 5-21)**: Complete with:
- Prerequisites linking to 6 prior chapters
- 7 specific learning objectives
- Time estimate (45-60 minutes)

**Section Structure**: 11 major sections with 22 subsections provide well-balanced progression:
1. Genetic Foundation of Target Selection
2. Network-Aware Target Discovery
3. Drug-Target Interaction Prediction
4. Toxicity Prediction
5. Functional Genomics Screens
6. Biomarker Development
7. Industry Workflows
8. Evaluation and Validation
9. Connections to Molecular Design
10. Prioritization, Not Automation (soft landing)

**Soft Landing (Lines 540-546)**: Uses tension-based title "Prioritization, Not Automation" (good). Provides three-beat closure with forward reference to @sec-ch31-design. Final sentence is quotable: "The transition from interpretation to design represents the frontier where foundation models become engines for creating biology, not just understanding it."

### Critical Style Violations

| Issue | Line | Text | Fix Required |
|-------|------|------|--------------|
| Em-dash (triple hyphen) | 32 | "2015---just 12 years" | Replace with parentheses |
| Em-dash (triple hyphen) | 583 | "automation---they identify" | Replace with colon or period |

### Gene Name Italicization Violations

| Gene | Lines | Count |
|------|-------|-------|
| PCSK9 | 28, 30, 32, 34, 399 | 5+ |
| MAP4K4 | 232, 234, 238 | 3 |
| RIPK1 | 292, 294, 301 | 3 |
| TP53 | 168 | 1 |
| STK11/LKB1 | 168 | 1 |

### Style Rule Compliance Checklist

- [x] No meta-commentary ("This chapter examines...")
- [x] No bullet points in prose (bullets appropriately contained in callouts)
- [x] No contractions found
- [x] No formulaic transitions (However, Moreover, etc.)
- [x] Leads with "why" before mechanisms
- [x] Model names properly italicized (*AlphaMissense*, *Enformer*, *ESM-2*, etc.)
- [ ] **FAIL**: Gene names not italicized
- [ ] **FAIL**: Em-dash violations (2 instances)

---

## Textbook Editor Report

**Grade: B+**

### Prose Quality

- **Sentence variety**: Good mix of short punchy sentences and longer technical explanations
- **Paragraph density**: Appropriate for graduate-level technical content
- **Voice consistency**: First-person plural used consistently throughout
- **Jargon introduction**: Key terms bolded on first use (variant effect predictor, genome-wide association study, linkage disequilibrium, etc.)

### Publication Readiness Fixes

| Line | Issue | Original | Suggested |
|------|-------|----------|-----------|
| 32 | Em-dash | "approval in 2015---just 12 years from gene discovery to approved drug, unusually fast" | "approval in 2015 (just 12 years from gene discovery to approved drug, unusually fast for novel targets)" |
| 583 | Em-dash | "prioritization, not automation---they identify what to test" | "prioritization, not automation: they identify what to test" |
| 28-34 | Gene format | PCSK9 | *PCSK9* |
| 168 | Gene format | STK11/LKB1 and TP53-related | *STK11*/*LKB1* and *TP53*-related |
| 232-238 | Gene format | MAP4K4 | *MAP4K4* |
| 292-301 | Gene format | RIPK1 | *RIPK1* |

### Positive Observations

- Zero contractions detected
- Zero false enthusiasm adjectives (exciting, remarkable, groundbreaking, etc.)
- Zero meta-commentary patterns
- Worked examples include concrete numbers (28%, 88%, 100,000 compounds, 23% hit rate, IC50 values)

---

## Pedagogy Review Report

**Grade: A**

### Learning Science Principle Assessment

| Principle | Rating | Evidence |
|-----------|--------|----------|
| **Cognitive Load** | Excellent | Complex pipelines broken into discrete steps; worked examples scaffold understanding |
| **Retrieval Practice** | Excellent | 4 "Stop and Think" prompts (lines 64, 220, 391); 2 "Knowledge Check" boxes with collapsible answers (lines 122, 333); comprehensive chapter-end test (lines 551-567) |
| **Interleaving** | Good | Explicit comparisons between single-gene vs. network approaches; traditional PRS vs. FM-enhanced |
| **Spacing** | Good | Backward references to Ch. 3, 13, 16, 17, 18, 22; forward hooks to Ch. 31 |
| **Elaborative Interrogation** | Strong | "Why" explanations accompany technical descriptions |
| **Concrete Examples** | Excellent | PCSK9 case study, Metformin repurposing, MAP4K4 DTI example, RIPK1 toxicity example, cardiovascular stratification example |
| **Dual Coding** | Good | 5 figures with descriptive captions |
| **Prior Knowledge Activation** | Strong | "Recall and Connect" callouts reference specific prior sections |
| **Metacognitive Scaffolds** | Excellent | Clear learning objectives, difficulty warnings (line 353), self-test questions |
| **Desirable Difficulties** | Good | Prediction prompts before answers |

### Drug Discovery Pipeline Clarity

The chapter maintains clear pedagogical progression through the drug discovery funnel:

1. **Why targets fail** (genetic validation motivation)
2. **Variant-to-gene aggregation** (technical foundation)
3. **Network approaches** (extended methodology)
4. **DTI prediction** (molecular application)
5. **Toxicity prediction** (safety considerations)
6. **Functional genomics** (experimental integration)
7. **Biomarkers** (clinical translation)
8. **Industry workflows** (practical deployment)

### Recommendations

- Consider adding a knowledge check in the Industry Workflows section (Section 30.7) which is currently pedagogy-light compared to other sections

---

## Fact Checker Report

**Grade: A**

### Citation Verification

All 12 citations verified present in `/root/gfm-book/bib/references.bib`:

| Citation Key | Lines Used | Status |
|--------------|------------|--------|
| nelson_support_2015 | 34, 572 | Verified |
| cheng_alphamissense_2023 | 69 | Verified |
| benegas_gpn-msa_2024 | 69 | Verified |
| avsec_alphagenome_2025 | 69 | Verified |
| brandes_genome-wide_2023 | 69 | Verified |
| wu_genome-wide_2024 | 71 | Verified |
| rakowski_mifm_2025 | 71 | Verified |
| ochoa_open_2023 | 97 | Verified |
| mountjoy_open_2021 | 111 | Verified |
| lin_esm-2_2022 | 215 | Verified |
| corso_diffdock_2022 | 217 | Verified |
| hie_efficient_2023 | 368 | Verified |

### Citation Gaps Identified

| Line | Claim | Status |
|------|-------|--------|
| 30 | PCSK9 loss-of-function: 28% LDL reduction, 88% CHD risk reduction | **Needs citation** (likely Cohen et al. 2006 NEJM) |
| 170 | Metformin cancer risk reduction (10-40%) | **Needs citation** |
| 442 | Regulatory acceptance of genomic biomarkers | **Needs citation** |

### Fact Verification

| Claim | Line | Status |
|-------|------|--------|
| "90% of drug candidates fail" | 3, 23 | Supported (industry standard) |
| "2x success rate for genetic targets" | 25, 42, 49 | Cited to Nelson 2015 |
| "FDA approval in 2015" for PCSK9 inhibitors | 32 | Verified (evolocumab Aug 2015, alirocumab Jul 2015) |
| "Phase II success rate ~25%" | 34 | Supported (industry benchmark) |

---

## Prose Doctor Report

**Grade: A-**

### AI Writing Symptom Scan

| Symptom | Count | Severity |
|---------|-------|----------|
| Em-dashes (---, --, em-dash) | 2 | **Critical** |
| Meta-commentary | 0 | Clean |
| False enthusiasm (exciting, remarkable, etc.) | 0 | Clean |
| Formulaic transitions (However, Moreover, etc.) | 0 | Clean |
| Hedging cascades | 0 | Clean |
| Passive voice overuse | Low | Acceptable |
| Anthropomorphization | 0 | Clean |
| Vague "This" sentence starters | Low | Acceptable |

### Critical Issues

| Line | Pattern | Original | Fix |
|------|---------|----------|-----|
| 32 | Triple-hyphen em-dash | "2015---just" | Use parentheses |
| 583 | Triple-hyphen em-dash | "automation---they" | Use colon or period |

### AI Pattern Analysis

- No GPT tells: "delve," "tapestry," "multifaceted"
- No Claude tells: overused "straightforward," "comprehensive"
- Strong active voice throughout
- Natural sentence rhythm without formulaic patterns
- Appropriate single hedges ("may," "can") without stacking

**Verdict**: Clean prose with minimal AI writing symptoms. Only em-dash violations require correction.

---

## Prioritized Action Items

### Critical (Block Release Until Fixed)

1. [ ] **Line 32**: Change `"received FDA approval in 2015---just 12 years from gene discovery to approved drug, unusually fast for novel targets"` to `"received FDA approval in 2015 (just 12 years from gene discovery to approved drug), unusually fast for novel targets"`

2. [ ] **Line 583**: Change `"prioritization, not *automation*---they identify what to test"` to `"prioritization, not *automation*: they identify what to test"` OR `"prioritization, not *automation*. They identify what to test"`

### High Priority (Before Publication)

3. [ ] **Lines 28, 30, 32, 34, 399**: Italicize all instances of PCSK9 to *PCSK9*
4. [ ] **Line 168**: Change `"STK11/LKB1 and TP53-related"` to `"*STK11*/*LKB1* and *TP53*-related"`
5. [ ] **Lines 232, 234, 238**: Italicize MAP4K4 to *MAP4K4*
6. [ ] **Lines 292, 294, 301**: Italicize RIPK1 to *RIPK1*
7. [ ] **Line 30**: Add citation for PCSK9 effect sizes (suggest: Cohen J et al. NEJM 2006)
8. [ ] **Line 170**: Add citation for metformin cancer risk statistics

### Medium Priority (Should Address)

9. [ ] **Line 442**: Add citation supporting regulatory acceptance of genomic biomarkers
10. [ ] Consider adding a Knowledge Check in Industry Workflows section

### Low Priority (Nice to Have)

11. [ ] Review line 108 table cell with single em-dash (acceptable but could use alternative)

---

## Review Coverage

| Agent | Status | Key Finding |
|-------|--------|-------------|
| chapter-auditor | Complete | 2 em-dash violations, gene italicization needed |
| textbook-editor | Complete | Typography fixes required, prose quality good |
| pedagogy-review | Complete | Excellent scaffolding, grade A |
| fact-checker | Complete | All citations verified, 3 gaps identified |
| prose-doctor | Complete | Clean prose, em-dashes only issue |
| course-designer | Skipped | Not in scope |
| figure-design | Partial | 5 figures present at expected paths |
| lean-out | Skipped | Chapter not overlong |

---

## Follow-Up Schedule

| Timeframe | Action |
|-----------|--------|
| Immediate | Fix 2 critical em-dash violations |
| This week | Apply all gene italicization fixes |
| Before publication | Add missing citations, run final style-check |
| Pre-publication | Full editorial-board re-review |

---

**Report generated by Editorial Board Agent**
**Date**: 2026-01-21
**Chapter**: p7-ch30-drug-discovery.qmd (591 lines)
**Word count**: ~8,500 words (estimated)

---

To save this report, create the directory and file:
```bash
mkdir -p /root/gfm-book/meta/reports
# Then save this content to /root/gfm-book/meta/reports/editorial-p7-ch30-2026-01-21.md
```
